TY  - JOUR

T1  - Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

JO  - PharmacoEconomics

UR  - http://eprints.whiterose.ac.uk/130271/

PY  - 2018/03/28

AU  - Rafia R

AU  - Pandor A

AU  - Davis S

AU  - Stevens JW

AU  - Harnan S

AU  - Clowes M

AU  - Sorour Y

AU  - Cutting R

ED  - 

DO  - DOI: 10.1007/s40273-018-0645-2

PB  - Springer Science and Business Media LLC

VL  - 36

IS  - 10

SP  - 1143

EP  - 1151

Y2  - 2024/10/19

ER  -